drugset / Trial / NCT05663411

A Study of SHR6508 in Secondary Hyperparathyroidism

NCT05663411

Phase 2 Unknown 75 enrolled Shanghai Hengrui Pharmaceutical Co., Ltd.
RandomizedParallel-groupOpen-labelTreatment

Summary

The study is being conducted to evaluate the efficacy and safety of SHR6508 for Chinese patients with secondary hyperparathyroidism of chronic kidney disease treated by maintenance hemodialysis.

Timeline

Start
2023-02-24
Primary completion
2023-10-31
Completion
2023-11-30

Drugs

EvaluationDrugModalityDoseRoute
Comparator Cinacalcet Other / unclassified
Subject SHR6508 Unknown